Suppr超能文献

针对 MCF-7 和 MDA-MB-231 乳腺癌细胞系的抗癌 SAR 模型。

Anticancer SAR models for MCF-7 and MDA-MB-231 breast cell lines.

机构信息

James Graham Brown Cancer Center, 529 South Jackson Street, University of Louisville, Louisville, KY 40202, U.S.A.

出版信息

Anticancer Res. 2011 Oct;31(10):3247-52.

Abstract

The National Cancer Institute's Developmental Therapeutics Program (DTP) maintains the screening results obtained in 60 standardized cancer cell lines for ~43,000 compounds. Here the application of the categorical structure-activity relationship (cat-SAR) program for the identification of the structural attributes of identified compounds that display differential cytostatic or cytotoxic activity to one breast cancer cell line and not another is reported. The goal of this approach is to separate features associated with antiproliferative activity towards many cell lines from those that affect only a specific cell type. To assess this approach, SAR models were developed for cytostatic and cytotoxic activity against the human breast cancer cell lines MCF-7 and MDAMB-231 and three differential activity models for compounds that were potent cytostatic and cytotoxic agents in MCF-7 cells, but relatively inactive against MDA-MB-231 cells. The MCF-7 and MDA-MB-231 models comprised the most potent 200 active and least potent 200 inactive compounds found in the DTP database and the differential activity models comprised 200 compounds potent in one cell line and not the other and 200 compounds equally potent between the cell lines. Leave-one-out validations of the individual MCF-7 and MDA-MB-231 models returned values between 83 and 85% concordance, with values obtained between 66 and 76% concordance for the differential activity models. The cat-SAR approach identified the chemical attributes associated with cytostatic and cytotoxic activity for the MCF-7 and MDA-MB-231 breast cancer cell lines included in the DTP and furthermore, were able to differentiate the selective activity of compounds between the two breast cancer lines. Thus it is conceivable that such cell line-specific mechanisms could be exploited for the discovery of highly specific anti-breast cancer agents and could also potentially facilitate the development of SAR models with sufficient resolution and clarity to identify chemical moieties associated with antiproliferative activity towards selective individual cancer types while being innocuous to other cell types.

摘要

美国国立癌症研究所的药物开发治疗学计划(DTP)保存了在 60 种标准化癌细胞系中对大约 43000 种化合物进行的筛选结果。本文报道了类别结构-活性关系(cat-SAR)程序在识别具有不同细胞抑制或细胞毒性活性的化合物的结构属性方面的应用,这些化合物对一种乳腺癌细胞系而不是另一种具有差异。这种方法的目的是将与许多细胞系的增殖抑制活性相关的特征与仅影响特定细胞类型的特征区分开来。为了评估这种方法,我们针对人乳腺癌细胞系 MCF-7 和 MDAMB-231 的细胞抑制和细胞毒性活性以及对 MCF-7 细胞具有强大的细胞抑制和细胞毒性作用但对 MDA-MB-231 细胞相对不活跃的化合物的三种差异活性模型,建立了 SAR 模型。 MCF-7 和 MDA-MB-231 模型包括 DTP 数据库中最有效 200 种活性化合物和最无效 200 种非活性化合物,差异活性模型包括在一种细胞系中有效而在另一种细胞系中无效的 200 种化合物和两种细胞系之间等效的 200 种化合物。对 MCF-7 和 MDA-MB-231 模型的逐个化合物进行的交叉验证返回的一致性值在 83%至 85%之间,对于差异活性模型,获得的一致性值在 66%至 76%之间。 cat-SAR 方法确定了与包括在 DTP 中的 MCF-7 和 MDA-MB-231 乳腺癌细胞系的细胞抑制和细胞毒性活性相关的化学属性,并且能够区分两种乳腺癌细胞系之间的化合物选择性活性。因此,可以想象,这种细胞系特异性机制可以用于发现高度特异性的抗乳腺癌药物,并且还可以潜在地促进 SAR 模型的开发,该模型具有足够的分辨率和清晰度,以识别与选择性个别癌症类型的增殖抑制活性相关的化学部分,同时对其他细胞类型无害。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验